Tatiana Vidaurre

Tatiana Vidaurre

Auto-generated profile, based on publicly available information

Tatiana Vidaurre

Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
KMKatie M. Marker
Katie M. Marker
VZValentina Zavala
Valentina Zavala
TVTatiana Vidaurre
Tatiana Vidaurre
PLPaul C. Lott
Paul C. Lott
JVJeannie Navarro Vásquez
Jeannie Navarro Vásquez
LFLaura Fejerman
Laura Fejerman
Women of Latin American origin in the United States are more likely to be diagnosed with advanced breast cancer and have a higher risk of mortality than non-Hispanic White women. Studies in U.S. Latinas and Latin American women have reported a high incidence of HER2 positive (+) tumors; however, the factors contributing to this observation are unknown. Genome-wide genotype data for 1,312 patients from the Peruvian Genetics and Genomics of Breast Cancer Study (PEGEN-BC) were used to estimate genetic ancestry. We tested the association between HER2 status and genetic ancestry using logistic and multinomial logistic regression models. Findings were replicated in 616 samples from Mexico and Colombia. Average Indigenous American (IA) ancestry differed by subtype. In multivariate models, the odds of having an HER2+ tumor increased by a factor of 1.20 with every 10% increase in IA ancestry proportion (95% CI, 1.07–1.35; P = 0.001). The association between HER2 status and IA ancestry was independently replicated in samples from Mexico and Colombia. Results suggest that the high prevalence of HER2+ tumors in Latinas could be due in part to the presence of population-specific genetic variant(s) affecting HER2 expression in breast cancer. Significance: The positive association between Indigenous American genetic ancestry and HER2+ breast cancer suggests that the high incidence of HER2+ subtypes in Latinas might be due to population and subtype-specific genetic risk variants.

1 October 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
TVTatiana Vidaurre
Tatiana Vidaurre
CSCarlos Santos
Carlos Santos
HGHenry Gómez
Henry Gómez
GSGustavo Sarria
Gustavo Sarria
EAEdgar Amorin
Edgar Amorin
JAJulio Abugattas
Julio Abugattas

17 October 2019 in Biomarkers in Medicine
Verified
Journal Article
Closed access
CCCarlos Castaneda
Carlos Castaneda
MCMiluska Castillo
Miluska Castillo
KAKarina Aliaga
Karina Aliaga
LBLuis A Bernabe
Luis A Bernabe
SCSandro Casavilca-Zambrano
Sandro Casavilca-Zambrano
HGHenry Guerra
Henry Guerra
Aim: To correlate levels of tumor-infiltrating lymphocytes (TIL) evaluated using the International Immuno-Oncology Biomarker Working Group methodology, and both density of tumor-infiltrating immune...

1 April 2026 in Nature Health
Verified
Journal Article
Open access
JHJorge Honles
Jorge Honles
Juan Pablo CerapioJuan Pablo Cerapio
Juan Pablo Cerapio
CMClaudia Monge
Claudia Monge
AMAgnes MARCHIO
Agnes MARCHIO
EREloy Ruiz
Eloy Ruiz
SBStéphane Bertani
Stéphane Bertani
Despite decades of concern over the carcinogenic potential of agricultural pesticides, toxicological studies relying on single endpoints have yet to establish a definitive link between environmental pesticide exposure and cancer in real-world contexts. Here we use an integrative spatial Bayesian framework that merges high-resolution environmental pesticide risk modelling with comprehensive cancer registry data to map pesticide-linked cancer clusters in Peru with unprecedented precision. Our process-based model, encompassing 31 key pesticide active ingredients, together with an innovative stratification of cancer cases by developmental lineage, reveals a robust spatial association between environmental pesticide exposure risk and cancer incidence. In pesticide-associated cancer hotspots, exposomic profiling of liver tissue—a primary target of chemical carcinogens—uncovers a distinct transcriptomic signature of pesticide exposure, implicating a non-genotoxic mode of action that disrupts core regulatory circuitries sustaining cell identity. Collectively, these findings strongly support a mechanistic link between pesticide exposure and cancer, challenging assumptions of human non-carcinogenicity derived from reductionist experimental models. This study redefines the exposome as a lineage-conditioned, mechanistically tractable framework and shows how complex pesticide mixtures can contribute to carcinogenic trajectories, with profound and far-reaching implications for global health policy and socio-ecological equity.

1 October 2022 in Future Oncology
Verified
Journal Article
Closed access
KRKatia Roque
Katia Roque
RRRossana Ruiz
Rossana Ruiz
IOIris Otoya-Fernandez
Iris Otoya-Fernandez
JGJosé Galarreta
José Galarreta
TVTatiana Vidaurre
Tatiana Vidaurre
HGHenry Leonidas Gomez
Henry Leonidas Gomez
Background: The COVID-19 pandemic caused discontinuities in cancer care (CC) in most countries. Here, the authors describe the real-world impacts of implementing a contingency plan employing teleme...

2 June 2022 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
VZValentina Zavala
Valentina Zavala
SCSandro Casavilca-Zambrano
Sandro Casavilca-Zambrano
JNJeannie Navarro-Vásquez
Jeannie Navarro-Vásquez
CCCarlos A. Castañeda
Carlos A. Castañeda
GVGuillermo Valencia
Guillermo Valencia
LFLaura Fejerman
Laura Fejerman
Background: Breast cancer incidence in the United States is lower in Hispanic/Latina (H/L) compared with African American/Black or Non-Hispanic White women. An Indigenous American breast cancer–protective germline variant (rs140068132) has been reported near the estrogen receptor 1 gene. This study tests the association of rs140068132 and other polymorphisms in the 6q25 region with subtype-specific breast cancer risk in H/Ls of high Indigenous American ancestry. Methods: Genotypes were obtained for 5,094 Peruvian women with (1,755) and without (3,337) breast cancer. Associations between genotype and overall and subtype-specific risk for the protective variant were tested using logistic regression models and conditional analyses, including other risk-associated polymorphisms in the region. Results: We replicated the reported association between rs140068132 and breast cancer risk overall [odds ratio (OR), 0.53; 95% confidence interval (CI), 0.47–0.59], as well as the lower odds of developing hormone receptor negative (HR−) versus HR+ disease (OR, 0.77; 95% CI, 0.61–0.97). Models, including HER2, showed further heterogeneity with reduced odds for HR+HER2+ (OR, 0.68; 95% CI, 0.51–0.92), HR−HER2+ (OR, 0.63; 95% CI, 0.44–0.90) and HR−HER2− (OR, 0.77; 95% CI, 0.56–1.05) compared with HR+HER2−. Inclusion of other risk-associated variants did not change these observations. Conclusions: The rs140068132 polymorphism is associated with decreased risk of breast cancer in Peruvians and is more protective against HR− and HER2+ diseases independently of other breast cancer-associated variants in the 6q25 region. Impact: These results could inform functional analyses to understand the mechanism by which rs140068132-G reduces risk of breast cancer development in a subtype-specific manner. They also illustrate the importance of including diverse individuals in genetic studies.